Optiverder made its binding offer as part of Kuro Biosciences’ planned capital increase. Optiverder, a Dutch investment firm, is set to acquire 2,808,718 shares at a subscription price of CHF 1.95 per share for an aggregate amount of just under CHF 5.5 million, according to a press release.
Kuros Biosciences has decided to preferably allocate the shares to Optiverder due to the investment firm’s early binding order and the size of its order. Kuros Biosciences will announce on Monday the number of shares for which rights have been exercised and the number of shares offered in the share placement.
Kuros Biosciences hopes to raise up to CHF 12 million with the capital increase. The new funds will go towards marketing its MagnetOs bone graft and further developing its product candidate Fibrin-PTH, which is used in spinal fusion.
A specialist in developing products for bone healing and tissue regeneration, Kuros Biosciences AG is a spin-off of the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETH) in Zurich. The company is located in the Bio-Technopark Schlieren-Zürich.